Yarrow Bioscience, Inc. — Form SCHEDULE 13D
Filed August 5, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 42/100
What the filing says
OrbiMed Advisors LLC and affiliated entities (OrbiMed Capital GP X LLC, OrbiMed Capital GP X LP, OrbiMed Genesis GP LLC) filed a joint Schedule 13D on July 27, 2026, indicating a reportable stake in Yarrow Bioscience common stock. The filing document itself contains only the joint filing agreement executed August 5, 2026, by Carl L. Gordon as member of OrbiMed Advisors LLC; specific share counts, percentage ownership, and acquisition details are not included in this exhibit.
Why this rating
Schedule 13D filing indicates meaningful stake by established VC firm, but absence of disclosed share count and % ownership prevents full assessment of materiality relative to $32M market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.